A Single Center, Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T (Provenge) as Neoadjuvant Treatment in Men With Localized Prostate Cancer.

Trial Profile

A Single Center, Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T (Provenge) as Neoadjuvant Treatment in Men With Localized Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2015

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms NeoACT
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Apr 2013 Planned End Date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top